Novartis Investigative site

Mendoza M5502EZA

0 studies enrolling now · 22 studies all time

What they study most

Acute Heart Failure, Asthma, Atherosclerotic Cardiovascular Disease, Chronic Heart Failure With Reduced Ejection Fraction, Chronic Obstructive Pulmonary Disease (COPD), Chronic Plaque Psoriasis, Moderate and Severe Plaque Psoriasis, Moderate to Severe Plaque-type Psoriasis, Nasal Polyps, Neoplasms, Breast, Non-Small Cell Lung Cancer, Pulmonary Disease, Chronic Obstructive

Studies at this site

• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma — Completed
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma — Stopped early
• Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients — Completed
• Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma — Stopped early
• Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma — Completed
• Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. — Completed
• Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis — Completed
• Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year — Completed
• ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer — Stopped early
• A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis — Completed
• Efficacy of QAX576 in Asthma — Completed
• Dose Finding Study for QAW039 in Asthma — Completed
• Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment — Stopped early
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
• Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab — Completed
• Global Non-interventional Heart Failure Disease Registry — Stopped early
• Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma — Completed
• Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201 — Stopped early
• Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease — Completed
• Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation. — Completed